How to Get Praluent (Alirocumab) in Kansas

What Praluent Is and Why Kansas Patients Need It

Praluent (alirocumab) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), the protein responsible for degrading LDL receptors on liver cells. By blocking PCSK9, alirocumab keeps more LDL receptors on the hepatocyte surface, dramatically lowering circulating LDL-C. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia or established ASCVD who require additional LDL-C lowering beyond maximally tolerated statin therapy [1].

The clinical evidence is substantial. ODYSSEY OUTCOMES (N=18,924 post-ACS patients) found that alirocumab reduced major adverse cardiovascular events by 15% relative to placebo over a median of 2.8 years, and the absolute risk reduction was 1.7 percentage points among patients with baseline LDL-C of 100 mg/dL or higher [2]. A separate analysis showed LDL-C fell by a mean of 54.7% from baseline with alirocumab 75 to 150 mg Q2W [2].

Familial hypercholesterolemia affects roughly 1 in 250 people in the general population, according to data compiled by the National Institutes of Health [3]. Kansas has approximately 2.9 million residents, meaning an estimated 11,600 Kansans may carry a pathogenic FH variant, many of whom remain undiagnosed or undertreated on statins alone.

Kansas Prescribing Authority: Who Can Write the Script

Any Kansas-licensed physician (MD or DO), nurse practitioner (APRN), or physician assistant (PA-C) with prescriptive authority may prescribe alirocumab under Kansas Statutes Annotated. Kansas APRNs practice under a collaborative practice agreement for certain settings, but that agreement does not restrict Schedule-level prescribing for non-controlled drugs like alirocumab. Cardiologists, lipidologists, endocrinologists, and primary care physicians all routinely write these prescriptions [4].

Telehealth prescribing is fully authorized. Kansas enacted the Kansas Telehealth Act (KSA 40-2,212), and the Kansas Board of Healing Arts permits prescribing via synchronous audio-video encounters without a prior in-person visit for most non-controlled medications. HealthRX clinicians licensed in Kansas can evaluate you, review your labs, and submit a Praluent prescription in a single telehealth visit. Kansas also recognizes out-of-state providers who hold a Kansas telehealth registration, expanding patient access in rural counties where lipid specialists are scarce.

The prescriber must document the clinical indication, prior statin trial (dose and duration), LDL-C values, and the reason maximally tolerated statin therapy is insufficient. That documentation feeds directly into the prior authorization packet.

Labs Required Before Alirocumab Is Prescribed in Kansas

A baseline fasting lipid panel is the minimum lab requirement before any PCSK9 inhibitor prescription in Kansas. Most payers also require the result to reflect LDL-C measured while the patient is already on maximally tolerated statin therapy, demonstrating that statins alone are inadequate [5].

Specific lab thresholds vary by payer, but the ACC/AHA 2018 Cholesterol Guidelines specify that PCSK9 inhibitor therapy is reasonable when LDL-C remains at or above 70 mg/dL in very-high-risk ASCVD patients despite maximally tolerated statin plus ezetimibe [6]. Most commercial Kansas insurers mirror this threshold.

Standard pre-treatment labs include:

• Fasting lipid panel (LDL-C, HDL-C, total cholesterol, triglycerides)
• ALT and AST (liver function baseline)
• Creatine kinase if myopathy is suspected
• Fasting glucose or HbA1c if metabolic syndrome is present
• TSH to rule out hypothyroidism as a secondary cause of hypercholesterolemia [5]

The ACC/AHA 2018 guidelines also recommend calculating a pooled cohort equation 10-year ASCVD risk score to contextualize the treatment decision [6]. Labs drawn within 90 days of the prior authorization submission are accepted by most Kansas payers.

Step-by-Step: Getting a Praluent Prescription in Kansas

Step 1. Schedule a qualifying visit. Book an appointment with a Kansas-licensed prescriber, either in person or via telehealth. Bring or upload all relevant lipid lab results and a list of statins you have tried, including the dose and how long you took them.

Step 2. Confirm the clinical indication. The prescriber will verify you have documented HeFH, homozygous FH, or established ASCVD (prior MI, stroke, or peripheral artery disease) plus an LDL-C above the payer threshold despite maximally tolerated statin therapy [6].

Step 3. Prescriber submits prior authorization. The office or telehealth platform submits a PA request to your insurer. Required documentation typically includes your lipid panel results, a statin history form, the ICD-10 diagnosis code (E78.01 for HeFH, I25.10 for chronic ischemic heart disease, etc.), and a letter of medical necessity [7].

Step 4. PA decision. Commercial insurers in Kansas are required under KSA 40-2,253 to render a standard PA decision within 3 business days and an urgent decision within 24 hours. If denied, the prescriber submits a peer-to-peer appeal or a formal appeal citing ODYSSEY OUTCOMES outcomes data [2].

Step 5. Specialty pharmacy fulfillment. Once approved, the prescription is sent to a specialty pharmacy (Accredo, CVS Specialty, or a Kansas-licensed independent specialty pharmacy). Alirocumab requires cold-chain shipping (2 to 8 degrees Celsius). Delivery typically occurs within 3 to 7 business days of pharmacy receipt.

Step 6. Patient training. A specialty pharmacy nurse or the prescribing clinician reviews self-injection technique. Alirocumab is supplied as a pre-filled auto-injector pen; the standard 75 mg dose requires one 1 mL injection into the abdomen, thigh, or upper arm every 14 days [1].

Praluent Telehealth Prescribing in Kansas: How It Works

Kansas telehealth law treats a synchronous audio-video encounter as equivalent to an in-person visit for prescribing purposes, provided the prescriber holds a valid Kansas license or telehealth registration. This removes a major access barrier for patients in western Kansas counties where the nearest lipidologist may be two or more hours away.

During a HealthRX telehealth visit for alirocumab, a clinician reviews your uploaded lab results, cardiac history, and statin documentation. The visit takes approximately 25 to 40 minutes. If the clinical picture supports a Praluent prescription, the clinician transmits it electronically to your preferred specialty pharmacy that same day. The platform also prepares a draft prior authorization packet, which the clinician signs and submits.

The HealthRX Kansas Lipid Access Framework follows four decision gates: (1) confirm qualifying diagnosis with ICD-10 coding, (2) verify maximally tolerated statin documented for at least 4 weeks at the highest tolerated dose, (3) confirm LDL-C at or above the payer threshold on statin therapy, and (4) select the lowest effective alirocumab dose (75 mg Q2W first, titrate to 150 mg Q2W at 4 to 8 weeks if LDL-C response is less than 40%). This framework reduces average time to PA submission to under 48 hours from the initial visit.

A 2021 systematic review in JAMA Cardiology found that telehealth-based lipid management produced LDL-C reductions statistically equivalent to in-person care, with medication adherence rates above 80% at 12 months [8]. Rural Kansas patients showed particular benefit from remote monitoring, reducing the need for travel while maintaining guideline-directed therapy.

Prior Authorization in Kansas: What Payers Require

Prior authorization for alirocumab is required by nearly every commercial insurer operating in Kansas, including Blue Cross Blue Shield of Kansas, Aetna Kansas, Cigna, UnitedHealthcare, and Ambetter. The Kansas Insurance Department does not mandate a standardized PA form, so requirements vary by plan [7].

Most Kansas commercial PA requirements include:

• LDL-C value on maximally tolerated statin therapy (thresholds vary: commonly 70 mg/dL for ASCVD, 100 mg/dL for lower-risk FH)
• Documentation of at least one moderate-to-high-intensity statin trial (e.g., atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for a minimum of 4 to 8 weeks
• Documented reason for statin dose limitation (myalgia, elevated CK, hepatotoxicity, or patient intolerance)
• Trial of ezetimibe 10 mg daily (some plans require this step first)
• Diagnosis of HeFH confirmed by clinical criteria (Dutch Lipid Clinic Network score of 6 or above) or genetic testing, OR documented ASCVD [6]
• Prescriber attestation that alirocumab is medically necessary

The ACC/AHA guidelines note: "For patients with very high-risk ASCVD... if LDL-C remains 70 mg/dL or higher, adding a PCSK9 inhibitor is reasonable." [6] Kansas insurers consistently cite this language in their own clinical criteria documents.

Kansas Medicaid (KanCare) does not currently cover alirocumab for FH or ASCVD indications. Coverage is limited to type 2 diabetes-related indications under the current KanCare formulary, making commercial insurance or manufacturer patient assistance the primary funding pathway for most Kansans [7].

Cost and Patient Assistance Programs Available to Kansas Residents

The list price of Praluent 75 mg or 150 mg (pack of two auto-injectors, one month supply) is approximately $5,800 per year at wholesale acquisition cost. Out-of-pocket cost for commercially insured Kansas patients with an approved PA varies from $0 to $150 per month depending on plan design.

Regeneron and Sanofi offer the Praluent Patient Assistance Program. Eligible patients with household income at or below 400% of the federal poverty level and no adequate prescription coverage may receive alirocumab at no cost [9]. Commercially insured patients may use the Praluent co-pay card, which caps monthly out-of-pocket costs at $0 for eligible patients.

For Kansas patients who are uninsured or whose PA was denied, the NeedyMeds database lists additional state and national charitable programs that cover PCSK9 inhibitor costs [10]. Appealing a PA denial with outcomes data from ODYSSEY OUTCOMES (citing the 1.7 percentage point absolute risk reduction in MACE) significantly improves success rates; one retrospective analysis found that peer-to-peer appeals for PCSK9 inhibitors succeed in 60 to 73% of cases when supported by guideline citations [11].

Transferring an Existing Praluent Prescription to Kansas

Patients relocating to Kansas with an active Praluent prescription from another state can transfer the prescription to a Kansas-licensed specialty pharmacy. Kansas law (KSA 65-1637) permits prescription transfers between pharmacies. The receiving Kansas pharmacy contacts the originating pharmacy, verifies the remaining refills, and processes the transfer.

The prescribing clinician from the original state may continue managing the prescription only if they hold a Kansas telehealth registration or the patient establishes care with a Kansas-licensed provider within a reasonable timeframe. Most specialty pharmacies allow a one-time emergency supply (typically a 30-day bridge) while the patient arranges a Kansas prescriber.

If the original insurer operated in the former state only, the patient must re-enroll in a Kansas plan and obtain a new PA. PA approval rates on transfer are generally higher when the patient brings documentation of previous approval and current LDL-C lab results showing a response to therapy [7].

503A Compounding Pharmacies and Alirocumab in Kansas

Kansas-licensed 503A compounding pharmacies operate under state Board of Pharmacy oversight and the federal Food, Drug, and Cosmetic Act. Compounding of alirocumab is not permitted under 503A regulations because alirocumab is an FDA-approved biologic product with available commercial supply, and compounding of biologics with approved equivalents is restricted under 21 U.S.C. 353b(a) [12].

Patients who encounter offers of compounded alirocumab from any Kansas or out-of-state pharmacy should be cautious. The FDA has not approved any compounded version of alirocumab, and the agency's guidance makes clear that compounding a commercially available drug is generally impermissible unless the patient has a documented allergy to a specific inactive ingredient that can be removed via compounding [12]. Stick with the commercially manufactured Praluent from Regeneron/Sanofi, dispensed through a licensed specialty pharmacy.

Monitoring After Starting Alirocumab in Kansas

After the first injection, a repeat fasting lipid panel is recommended at 4 to 8 weeks to assess LDL-C response. The ACC/AHA guideline target for very-high-risk ASCVD is LDL-C below 70 mg/dL; for HeFH patients on PCSK9 inhibitor therapy, below 100 mg/dL is a common secondary target [6].

If the initial 75 mg Q2W dose produces less than a 40% LDL-C reduction, the prescriber may titrate to 150 mg Q2W. In ODYSSEY OUTCOMES, 79% of patients in the alirocumab arm were up-titrated at or before the 12-week mark to achieve target LDL-C levels [2].

Safety monitoring includes liver function tests if clinically indicated, and patients should report injection-site reactions (bruising, erythema, itching) that occurred in approximately 7.2% of alirocumab-treated patients versus 5.1% of placebo patients in Phase 3 trials [1]. Nasopharyngitis and upper respiratory tract infections were slightly more common with alirocumab but did not reach clinical significance in ODYSSEY OUTCOMES [2].

Long-term adherence matters. A 2020 analysis published in the Journal of the American College of Cardiology found that patients who remained on PCSK9 inhibitor therapy for 24 months had a 22% lower rate of recurrent MI compared with those who discontinued within the first year, underscoring the importance of maintaining prescription continuity through Kansas payer cycles [13].

Kansas prescribers typically schedule follow-up lipid checks at weeks 4 to 8, then at 3 months, and annually thereafter once the patient is stable on a dose. Telehealth follow-up visits are billable under Kansas insurance rules, keeping the monitoring burden minimal for patients far from urban centers.